{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:25:24Z","timestamp":1783329924998,"version":"3.54.6"},"reference-count":39,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>The widespread adoption of prostate-specific membrane antigen (PSMA)-targeted PET\/CT has profoundly reshaped molecular imaging in prostate cancer and has substantially reduced the routine use of radiolabeled choline tracers. However, the transition from choline to PSMA imaging should not be interpreted simply as the replacement of one radiopharmaceutical by another, but rather as part of a broader evolution from metabolism-based imaging toward receptor-targeted and biology-driven imaging strategies. This narrative review critically reassesses the residual and emerging role of choline PET\/CT in the PSMA era, with particular attention to the biological rationale of choline uptake, selected prostate cancer scenarios, and extra-prostatic applications. In prostate cancer, PSMA PET\/CT remains the dominant imaging modality because of its superior diagnostic performance, particularly in biochemical recurrence; nevertheless, choline PET\/CT may provide complementary metabolic information in highly selected settings, including PSMA-low or heterogeneous disease, aggressive or dedifferentiated variants, neuroendocrine transformation, equivocal PSMA findings, and limited PSMA availability. These prostate cancer applications, however, are supported mainly by biological rationale, indirect evidence, and limited clinical data and should therefore be regarded as exploratory rather than established indications. By contrast, 18F-fluorocholine PET\/CT has emerged as a clinically established imaging modality in primary hyperparathyroidism, particularly after negative or inconclusive conventional imaging, with prospective studies and meta-analyses demonstrating high detection rates and superior performance compared with conventional scintigraphic techniques. Additional applications in hepatocellular carcinoma and selected neuro-oncologic settings remain exploratory and require further validation. Overall, choline PET\/CT should not be considered obsolete in the PSMA era, but selectively repositioned within biology-driven and multiparametric imaging strategies, with its strongest evidence currently supporting primary hyperparathyroidism and its other applications requiring cautious interpretation and further prospective validation.<\/jats:p>","DOI":"10.3390\/diagnostics16132108","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:05:38Z","timestamp":1783325138000},"page":"2108","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Choline PET\/CT in the PSMA Era: Clinical Repositioning, Biological Perspectives, and Emerging Applications"],"prefix":"10.3390","volume":"16","author":[{"given":"Virginia","family":"Rossetti","sequence":"first","affiliation":[{"name":"Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7333-5701","authenticated-orcid":false,"given":"Lorenzo","family":"Fantini","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Marini","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0338-800X","authenticated-orcid":false,"given":"Monica","family":"Celli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-7670","authenticated-orcid":false,"given":"Ilaria","family":"Grassi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-262X","authenticated-orcid":false,"given":"Maddalena","family":"Sansovini","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3960-7737","authenticated-orcid":false,"given":"Silvia","family":"Nicolini","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7455-6253","authenticated-orcid":false,"given":"Federica","family":"Matteucci","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Caroli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/MNM.0000000000001770","article-title":"Comparison of 18F-PSMA-1007 and 18F-choline PET\/CT in prostate cancer patients with biochemical recurrence: A phase 3, prospective, multicenter, randomized study","volume":"44","author":"Panagiotidis","year":"2023","journal-title":"Nucl. Med. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.3390\/curroncol30070464","article-title":"Head-to-head comparison of [18F]F-choline and imaging of prostate-specific membrane antigen, using [18F]DCFPyL PET\/CT, in patients with biochemical recurrence of prostate cancer","volume":"30","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142024 update: Treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.110.077941","article-title":"Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline","volume":"52","author":"Jadvar","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2013.04.019","article-title":"The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET\/CT in prostate cancer: A systematic review and meta-analysis","volume":"64","author":"Umbehr","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","article-title":"Choline PET or PET\/CT and biochemical relapse of prostate cancer: A systematic review and meta-analysis","volume":"38","author":"Evangelista","year":"2013","journal-title":"Clin. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrc3162","article-title":"Choline metabolism in malignant transformation","volume":"11","author":"Glunde","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: Joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2967\/jnumed.121.263274","article-title":"The VISION forward: Recognition and implication of PSMA\u2212\/18F-FDG+ metastatic castration-resistant prostate cancer","volume":"63","author":"Jadvar","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2019","journal-title":"Endocr. Relat. Cancer."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2967\/jnumed.119.229914","article-title":"18F-fluorocholine PET\/CT in primary hyperparathyroidism: Superior diagnostic performance to conventional scintigraphic imaging for localization of hyperfunctioning parathyroid glands","volume":"61","author":"Cuderman","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s12020-020-02487-y","article-title":"Will 18F-fluorocholine PET\/CT replace other methods of preoperative parathyroid imaging?","volume":"71","author":"Giovanella","year":"2021","journal-title":"Endocrine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00259-018-4123-z","article-title":"Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: A systematic review and meta-analysis","volume":"46","author":"Treglia","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: The EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","article-title":"PSMA-RADS version 1.0: A step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies","volume":"73","author":"Rowe","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.18383\/j.tom.2018.00021","article-title":"Pitfalls in gallium-68 PSMA PET\/CT interpretation: A pictorial review","volume":"4","author":"Shetty","year":"2018","journal-title":"Tomography"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13550-020-00745-8","article-title":"The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: Validation of the PSMA-RADS version 1.0","volume":"11","author":"Kuten","year":"2021","journal-title":"EJNMMI Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2214\/AJR.06.0938","article-title":"Parathyroid imaging: Technique and role in the preoperative evaluation of primary hyperparathyroidism","volume":"188","author":"Johnson","year":"2007","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1007\/s00259-018-3980-9","article-title":"18F-fluorocholine PET\/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT\/CT: A prospective dual-centre study in 100 patients","volume":"45","author":"Beheshti","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s00259-018-4018-z","article-title":"Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: The added value of 18F-fluorocholine PET\/CT","volume":"45","author":"Grimaldi","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.semnuclmed.2024.08.002","article-title":"18F-fluorocholine-positron emission tomography\/computerized tomography (FCH PET\/CT) imaging for detecting abnormal parathyroid glands: Indication, practice, interpretation and diagnostic performance","volume":"54","author":"Noskovicova","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00259-017-3911-1","article-title":"F18-choline PET\/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT\/CT are negative or inconclusive: The APACH1 study","volume":"45","author":"Quak","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1007\/s00259-021-05334-y","article-title":"The EANM practice guidelines for parathyroid imaging","volume":"48","author":"Giovanella","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s00259-018-4147-4","article-title":"Additional value of integrated 18F-choline PET\/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile","volume":"46","author":"Piccardo","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejso.2016.09.016","article-title":"Focused parathyroidectomy without intraoperative parathormone testing is safe after pre-operative localization with 18F-fluorocholine PET\/CT","volume":"43","author":"Hocevar","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/RLU.0000000000000607","article-title":"Localization of parathyroid adenoma by 11C-choline PET\/CT: Preliminary results","volume":"39","author":"Orevi","year":"2014","journal-title":"Clin. Nucl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2967\/jnumed.108.052639","article-title":"Detection of hepatocellular carcinoma using 11C-choline PET: Comparison with 18F-FDG PET","volume":"49","author":"Yamamoto","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ghidaglia, J., Golse, N., Pascale, A., Sebagh, M., and Besson, F.L. (2022). 18F-FDG\/18F-choline dual-tracer PET behavior and tumor differentiation in hepatocellular carcinoma: A systematic review. Front. Med., 9.","DOI":"10.3389\/fmed.2022.924824"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2967\/jnumed.110.075507","article-title":"Detection of hepatocellular carcinoma with PET\/CT: A prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease","volume":"51","author":"Talbot","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_30","first-page":"206","article-title":"Towards refining the utility of dual (18F-FDG\/18F-choline) PET\/CT for the management of hepatocellular carcinoma: A tertiary center study","volume":"67","author":"Besson","year":"2023","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3325\/cmj.2021.62.310","article-title":"18F-FET and 18F-choline PET-CT in patients with MRI-suspected low-grade gliomas: A pilot study","volume":"62","author":"Nemir","year":"2021","journal-title":"Croat. Med. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e11556","DOI":"10.1097\/MD.0000000000011556","article-title":"Accuracy of 11C-choline positron emission tomography in differentiating glioma recurrence from radiation necrosis: A systematic review and meta-analysis","volume":"97","author":"Gao","year":"2018","journal-title":"Medicine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2176\/nmc.oa2013-0117","article-title":"Comparison of 11C-methionine, 11C-choline, and 18F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis","volume":"54","author":"Takenaka","year":"2014","journal-title":"Neurol. Med. Chir."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","article-title":"Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: Version 1.0","volume":"46","author":"Law","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Filippi, L., Frantellizzi, V., Chiaravalloti, A., Pontico, M., De Feo, M.S., Corica, F., Montebello, M., Schillaci, O., De Vincentis, G., and Bagni, O. (2021). Prognostic and theranostic applications of positron emission tomography for a personalized approach to metastatic castration-resistant prostate cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063036"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.semnuclmed.2023.06.004","article-title":"Future imaging of prostate cancer: Do we need more than PSMA PET\/CT?","volume":"54","author":"Vetrone","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2967\/jnumed.118.222893","article-title":"Introduction to radiomics","volume":"61","author":"Mayerhoefer","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: Images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: The bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/13\/2108\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:05:42Z","timestamp":1783328742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/13\/2108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":39,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["diagnostics16132108"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16132108","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}